New mRNA vaccine trial targets mpox outbreaks in africa
NCT ID NCT07379580
Summary
This study is testing a new mpox vaccine made with mRNA technology, similar to some COVID-19 vaccines. It aims to see if the vaccine is safe and if it triggers a strong immune response in healthy adults, both those who have and have not been exposed to related viruses before. About 310 participants in African countries will receive two shots or a placebo over 14 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPOX (MONKEYPOX) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Desmond Tutu Health Foundation Masiphumelele Clinic
NOT_YET_RECRUITINGCape Town, 7975, South Africa
-
Institute National de Recherche Biomedicale
NOT_YET_RECRUITINGKinshasa, 5345, Democratic Republic of the Congo
-
Perinatal HIV Research Unit
RECRUITINGJohannesburg, 1864, South Africa
-
TASK Applied Science
NOT_YET_RECRUITINGCape Town, 7405, South Africa
-
TREAD Research Pty Ltd
RECRUITINGCape Town, 7530, South Africa
-
University of Kinshasa UNIKIN
NOT_YET_RECRUITINGKinshasa, 01306, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.